Ovid Therapeutics Inc. (OVID) Operating Margin
- Operating margin · 12 months: Value -3686.54%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -3686.54% | Operating income / revenue. Period ending 2026-06-30. $-58.36M ÷ $1.58M × 100 ≈ -3686.54% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -58.36M USD | Operating Income (Loss) |
| Revenue | 1.58M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 33.60M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-58.36M | $1.58M | (m) | $33.60M | (m) | -3686.54% |
| 2026-03-31 | $-47.73M | $7.12M | (m) | $30.10M | (m) | -670.25% |
| 2025-12-31 | $-42.44M | $7.25M | (m) | $25.58M | (m) | -585.20% |
| 2025-09-30 | $-40.87M | $6.61M | (m) | $24.92M | (m) | -618.28% |
| 2025-06-30 | $-41.57M | $6.65M | (m) | $26.91M | (m) | -625.08% |
| 2025-03-31 | $-57.02M | $548.00K | (m) | $33.03M | (m) | -10404.74% |
| 2024-12-31 | $-61.88M | $566.00K | (m) | $36.77M | (m) | -10933.75% |
| 2024-09-30 | $-69.35M | $631.70K | (m) | $41.49M | (m) | -10978.63% |
| 2024-06-30 | $-68.15M | $567.70K | (m) | $38.96M | (m) | -12004.94% |
| 2024-03-31 | $-61.81M | $473.69K | (m) | $32.37M | (m) | -13047.73% |
| 2023-12-31 | $-59.28M | $391.69K | (m) | $28.59M | (m) | -15134.60% |
| 2023-09-30 | $-53.27M | $296.41K | (m) | $23.50M | (m) | -17970.27% |
| 2023-06-30 | $-54.04M | $198.54K | (m) | $23.35M | (m) | -27218.95% |
| 2023-03-31 | $-54.17M | $123.54K | (m) | $23.40M | (m) | -43850.16% |
| 2022-12-31 | $-55.55M | $1.50M | (m) | $24.62M | (m) | -3696.44% |
| 2022-09-30 | $-69.73M | (m) | (m) | $37.15M | (m) | (m) |
| 2022-06-30 | $-68.61M | (m) | (m) | $36.89M | (m) | (m) |
| 2022-03-31 | $-68.62M | (m) | (m) | $38.52M | (m) | (m) |
| 2021-12-31 | $124.21M | (m) | (m) | $46.94M | (m) | (m) |
| 2021-09-30 | $128.97M | (m) | (m) | $45.73M | (m) | (m) |
| 2021-06-30 | $124.25M | (m) | (m) | $56.69M | (m) | (m) |
| 2021-03-31 | $115.42M | (m) | (m) | $65.04M | (m) | (m) |
| 2020-12-31 | $-81.43M | (m) | (m) | $63.42M | (m) | (m) |
| 2020-09-30 | $-77.11M | (m) | (m) | $58.64M | (m) | (m) |
| 2020-06-30 | $-77.47M | (m) | (m) | $54.36M | (m) | (m) |
| 2020-03-31 | $-67.65M | (m) | (m) | $47.45M | (m) | (m) |
| 2019-12-31 | $-61.41M | (m) | (m) | $42.16M | (m) | (m) |
| 2019-09-30 | $-57.27M | (m) | (m) | $38.67M | (m) | (m) |
| 2019-06-30 | $-53.67M | (m) | (m) | $35.65M | (m) | (m) |
| 2019-03-31 | $-53.56M | (m) | (m) | $34.65M | (m) | (m) |
| 2018-12-31 | $-52.93M | (m) | (m) | $33.79M | (m) | (m) |
| 2018-09-30 | $-50.85M | (m) | (m) | $31.88M | (m) | (m) |
| 2018-06-30 | $-47.10M | (m) | (m) | $29.20M | (m) | (m) |
| 2018-03-31 | $-44.18M | (m) | (m) | $27.16M | (m) | (m) |
| 2017-12-31 | $-65.01M | (m) | (m) | $49.97M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | $39.74M | (m) | (m) |
| 2016-12-31 | $-22.54M | (m) | (m) | $9.59M | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-13.19M | (m) | (m) | $6.61M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |